|
|||||
|
|
LY3437943, a novel triple glucagon,GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept |
|
| Institution: | 1. Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA;2. Eli Lilly and Company, Vienna, Austria |
| Abstract: |  |
| Keywords: | triple agonist GIP GLP-1 glucagon obesity glucose control energy expenditure metabolomics |
| 本文献已被 ScienceDirect 等数据库收录！ | |